Insider Cluster (2 insiders) ·Filed Apr 15, 2026

KYMR

Kymera Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $315K total
Actionable Insight • Neutral

Monitor next 10-Q for updates on pipeline progress or cash position, as current insider sales are routine and not materially bearish. No immediate catalyst implied, but continued selling ahead of earnings or dilutive financing could shift sentiment.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
KYMR ▲ +34.10% at T+60d
NEUTRAL call ✓ call won +34.10% · α vs SPY +25.96% · entry $89.00 → $119.35
Entry anchored
Apr 14, 03:59 PM ET
via exchange tick
T+1d
-3.21%
call -3.21% · α -3.47%
$86.14
settled 6mo ago
T+5d
-0.26%
call -0.26% · α -1.90%
$88.77
settled 5mo ago
T+20d
-6.12%
call -6.12% · α -12.17%
$83.55
settled 5mo ago
T+60d
+34.10%
call +34.10% · α +25.96%
$119.35
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two insiders at Kymera Therapeutics sold a combined $315K in shares within a 7-day window, including COO Chadwick Jeremy G and Director Bruce Booth. The sales represent a modest 0.004% of the company's $7.1B market cap and align with recent open-market dispositions, suggesting routine portfolio management rather than a strong negative signal.

Key Financial Metrics

Direction
selling
Total Value
$315.0K
Insiders
2

Key Facts

  • COO Chadwick Jeremy G sold 1,300 shares for $117K on 2026-04-15 and exercised/withheld shares on 2026-04-22 (non-cash transactions totaling $3,017)
  • Director Bruce Booth sold 2,200 shares for $198K on 2026-04-15
  • Total open-market sales in cluster: $315K
  • Cluster value represents 0.004% of $7.1B market cap
  • Recent 30-day insider activity includes $342K in total sales, indicating ongoing selling pressure

Financial Impact

$315,000 in open-market sales (0.004% of market cap)

insider ownershipmarket sentiment

Risk Factors

  • Prolonged insider selling could erode investor confidence
  • Biotech stocks are sensitive to cash runway and clinical trial updates

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KYMR-1777062653014
30 reports for KYMR
Performance horizon
67% Hit rate 8 of 12 directional calls best @ T+60▲ +60.99%Jun 8, 2026
Filters
Rows
Reports for KYMR — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
8-K
BULLISH ★ 6/10
$105.48 $118.63▲ +12.47%▲ +13.07%$107.44 (+1.86%)
Jul 8, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$114.16 $105.48▲ +7.60%▲ +10.88%$107.44 (+5.88%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 6/10
$113.51 $107.01▲ +5.73%▲ +5.31%$107.44 (+5.34%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 5/10
$113.51 $107.01▲ +5.73%▲ +5.31%$107.44 (+5.34%)
Jun 30, 2026
13w ago
144
BEARISH ★ 4/10
$114.20 $105.25▲ +7.84%▲ +5.65%$107.44 (+5.92%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 4/10
$114.67 $110.05▼ −4.03%▼ −3.00%$107.44 (−6.30%)
Jun 26, 2026
13w ago
Insider Cluster
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.44 (+1.72%)
Jun 26, 2026
13w ago
144
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.44 (+1.72%)
Jun 26, 2026
13w ago
144
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.44 (+1.72%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$116.46 $110.38▼ −5.22%▼ −5.75%$107.44 (−7.74%)
Showing 10 of 30

US Market Status

Market Open — Closes in 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 24, 2026